Evidence mapPaperPMID 30828432Full record

ReviewF1000Research2019

An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy.

Shazli Azmi, Ioannis N Petropoulos, Maryam Ferdousi, Georgios Ponirakis, Uazman Alam, Rayaz A Malik

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06524284 (Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06524284 nacompletednot on this mapstarted 2024, after this paper: background citation

Feasibility of Self-treatment of Painful Diabetic Neuropathy Using Electrical Vasomotor Nerve Stimulation

TypeinterventionalSponsorNeurecon BVRan2024 to 2025Enrolled40ConditionsPainful Diabetic NeuropathyArmsReleaf
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Melatonin signalling in Schwann cells during neuroregeneration.Frontiers in cell and developmental biology · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Genetic and Epigenomic Modifiers of Diabetic Neuropathy.International journal of molecular sciences · 2021
    Review
  12. Review
  13. Molecular Mechanism ofFrontiers in pharmacology · 2021
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Cardiac Autonomic Neuropathy in Obesity, the Metabolic Syndrome and Prediabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019 · on this map
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Shazli AzmiInstitute of Cardiovascular Sciences, University of Manchester and Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.ORCID 0000-0002-1789-6988
Ioannis N PetropoulosWeill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Maryam FerdousiInstitute of Cardiovascular Sciences, University of Manchester and Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Georgios PonirakisWeill Cornell Medicine-Qatar, Education City, Qatar Foundation, Doha, Qatar.
Uazman AlamDepartment of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK.
Rayaz A MalikInstitute of Cardiovascular Sciences, University of Manchester and Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Manchester Academic Health Science Centre · GBWeill Cornell Medical College in Qatar · QAUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes. It poses a significant challenge for clinicians as it is often diagnosed late when patients present with advanced consequences such as foot ulceration. Autonomic neuropathy (AN) is also a frequent and under-diagnosed complication unless it is overtly symptomatic. Both somatic and autonomic neuropathy are associated with increased mortality. Multiple clinical trials have failed because of limited efficacy in advanced disease, inadequate trial duration, lack of effective surrogate end-points and a lack of deterioration in the placebo arm in clinical trials of DPN. Multifactorial risk factor reduction, targeting glycaemia, blood pressure and lipids can reduce the progression of DPN and AN. Treatment of painful DPN reduces painful symptoms by about 50% at best, but there is limited efficacy with any single agent. This reflects the complex aetiology of painful DPN and argues for improved clinical phenotyping with the use of targeted therapy, taking into account co-morbid conditions such as anxiety, depression and sleep disturbance.

Indexed as

Diabetes MellitusDiabetic NeuropathiesSleep Wake DisordersHumansPainRisk Factorsautonomic neuropathydiabetes mellitusperipheral neuropathy

Identifiers

PMID30828432
PMCPMC6381801
OpenAlexW2912676989

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.